Time effect of rutaecarpine on caffeine pharmacokinetics in rats.
Rutaecarpine is reported as a potent inducer of CYP1A2 enzyme in rats. There are natural herbal supplements containing rutaecarpine that are designed to enhance the CYP1A2-dependent removal of caffeine from blood so that people can have coffee later in the day without causing sleep interference. This study aimed to determine the minimum amount of time needed from oral rutaecarpine administration until the observed effect of rutaecarpine on caffeine pharmacokinetics (PK) in 15 male Sprague-Dawley rats. PK parameters for caffeine and its metabolites in the control and rutaecarpine groups were calculated using WinNonlin®. Results showed that orally administered rutaecarpine at 100 mg/kg dose as early as 3 h before oral caffeine administration significantly decreased the oral systemic exposure and mean residence time of caffeine and its metabolites due to decreased caffeine bioavailability (by up to 75%) and increased clearance. The systemic exposure of caffeine and its metabolites were also decreased when caffeine was given intravenously, though this effect was less pronounced than when caffeine was given orally. Although plasma level of rutaecarpine was undetectable (less than 10 ng/mL), rutaecarpine still induced hepatic CYP1A2 activity. Results from 7-methoxyresorufin O-demethylation activity, which is specific to CYP1A2, showed that 3 h after one rutaecarpine oral dose, CYP1A2 activity in rat liver tissue was increased by 3- fold. This finding suggested that rutaecarpine effectively induced CYP1A2 activity in the liver.
['Estari|Rohit Kumar|RK|', 'Dong|Jin|J|', 'Chan|William K|WK|', 'Park|Miki Susanto|MS|', 'Zhou|Zhu|Z|']
Rutaecarpine Caffeine Rat CYP1A2 AHR, aryl hydrocarbon receptor ANOVA, Analysis of variance BCA, Bicinchoninic acid CYP, cytochrome P450 GI, gastrointestinal tract MROD, 7-methoxyresorufin O-demethylation Time-dependent induction intravenous, IV pharmacokinetics, PK